These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30660699)

  • 21. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
    Cho N; Razipour SE; McCain ML
    Exp Biol Med (Maywood); 2018 Apr; 243(7):601-612. PubMed ID: 29504479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix Stiffness: the Conductor of Organ Fibrosis.
    Santos A; Lagares D
    Curr Rheumatol Rep; 2018 Jan; 20(1):2. PubMed ID: 29349703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the peptides Relaxin, Neuregulin, Ghrelin and Glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction.
    Warbrick I; Rabkin SW
    Peptides; 2019 Jan; 111():33-41. PubMed ID: 29807087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triazine herbicides inhibit relaxin signaling and disrupt nitric oxide homeostasis.
    Park SE; Lim SR; Choi HK; Bae J
    Toxicol Appl Pharmacol; 2016 Sep; 307():10-18. PubMed ID: 27431321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Host responses in tissue repair and fibrosis.
    Duffield JS; Lupher M; Thannickal VJ; Wynn TA
    Annu Rev Pathol; 2013 Jan; 8():241-76. PubMed ID: 23092186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relaxin: an endogenous renoprotective factor?
    Hewitson TD; Samuel CS
    Ann N Y Acad Sci; 2009 Apr; 1160():289-93. PubMed ID: 19416206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Ho WY; Samuel CS
    Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The double-edged role of IL-22 in organ fibrosis.
    Chen J; Lodi R; Zhang S; Su Z; Wu Y; Xia L
    Immunopharmacol Immunotoxicol; 2020 Oct; 42(5):392-399. PubMed ID: 32689851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.
    Frangogiannis NG
    Mol Aspects Med; 2019 Feb; 65():70-99. PubMed ID: 30056242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
    Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
    Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resolution of organ fibrosis.
    Jun JI; Lau LF
    J Clin Invest; 2018 Jan; 128(1):97-107. PubMed ID: 29293097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.
    Sasser JM
    Kidney Int; 2014 Jul; 86(1):9-10. PubMed ID: 24978374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular players in lung fibrosis.
    Lekkerkerker AN; Aarbiou J; van Es T; Janssen RA
    Curr Pharm Des; 2012; 18(27):4093-102. PubMed ID: 22630084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of sphingosine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin.
    Frati A; Ricci B; Pierucci F; Nistri S; Bani D; Meacci E
    Mol Endocrinol; 2015 Jan; 29(1):53-67. PubMed ID: 25415609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosis uncovered: ADAMTS12 cuts to the core of extracellular matrix drama.
    Dumoulin B; Susztak K
    J Clin Invest; 2024 Sep; 134(18):. PubMed ID: 39286974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The myofibroblast matrix: implications for tissue repair and fibrosis.
    Klingberg F; Hinz B; White ES
    J Pathol; 2013 Jan; 229(2):298-309. PubMed ID: 22996908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the Relaxin Pathway for Liver Disease Treatment.
    Bennett RG
    Eur Med J Hepatol; 2018 May; 6(1):80-87. PubMed ID: 31360529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling.
    Svystonyuk DA; Ngu JM; Mewhort HE; Lipon BD; Teng G; Guzzardi DG; Malik G; Belke DD; Fedak PW
    J Transl Med; 2015 May; 13():147. PubMed ID: 25948488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relaxin and the extracellular matrix: molecular mechanisms of action and implications for cardiovascular disease.
    McGuane JT; Parry LJ
    Expert Rev Mol Med; 2005 Sep; 7(21):1-18. PubMed ID: 16191259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.